UK pharma giant GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion
GSK Plc agreed to buy Nuvalent Inc. in a deal valued at $10.6 billion, adding a biotech firm that’s developing treatments for lung cancer as the British pharmaceutical company seeks to rebuild its oncology franchise. GSK to acquire Nuvalent for $10.6B to boost cancer treatments (REUTERS) GSK will pay $124 a share in cash for…
